Abstract
Poly-N-acetyllactosamine structures occur in mammalian glycoproteins in both N- and O-linked glycans. They represent a backbone for additional modifications by fucosyltransferases, sialyltransferases and sulfotransferases. These glycans have been suggested to be involved in biospecific interactions with selectins and other glycan-binding proteins. Moreover, the poly-Nacetyllactosamine chains in N-glycans have been found to promote tumor progression and metastasis. Poly-N-acetyllactosamine chains are synthesized by repeated alternating additions of Nacetylglucosamine and galactose, catalyzed by β-1,3-N-acetylglucosaminyltransferases (poly-N-acetyllactosamine synthase) and β-1,4-galactosyltransferases. This review describes the poly-N-acetyllactosamine assembling machinery and focuses on recent advances in the molecular cloning and characterization of poly-N-acetyllactosamine synthase gene families. Recent progress in revealing the biological functions of poly-N-acetyllactosamine structures by various approaches in vitro and in vivo using different model systems has also been summarized.
Keywords: poly-n-acetyllactosamine, 3-n-acetylglucosaminyltransferase, 4-galactosyltransferase
Current Protein & Peptide Science
Title: Why are Glycoproteins Modified by Poly-N-Acetyllactosamine Glycoconjugates?
Volume: 4 Issue: 1
Author(s): Dapeng Zhou
Affiliation:
Keywords: poly-n-acetyllactosamine, 3-n-acetylglucosaminyltransferase, 4-galactosyltransferase
Abstract: Poly-N-acetyllactosamine structures occur in mammalian glycoproteins in both N- and O-linked glycans. They represent a backbone for additional modifications by fucosyltransferases, sialyltransferases and sulfotransferases. These glycans have been suggested to be involved in biospecific interactions with selectins and other glycan-binding proteins. Moreover, the poly-Nacetyllactosamine chains in N-glycans have been found to promote tumor progression and metastasis. Poly-N-acetyllactosamine chains are synthesized by repeated alternating additions of Nacetylglucosamine and galactose, catalyzed by β-1,3-N-acetylglucosaminyltransferases (poly-N-acetyllactosamine synthase) and β-1,4-galactosyltransferases. This review describes the poly-N-acetyllactosamine assembling machinery and focuses on recent advances in the molecular cloning and characterization of poly-N-acetyllactosamine synthase gene families. Recent progress in revealing the biological functions of poly-N-acetyllactosamine structures by various approaches in vitro and in vivo using different model systems has also been summarized.
Export Options
About this article
Cite this article as:
Zhou Dapeng, Why are Glycoproteins Modified by Poly-N-Acetyllactosamine Glycoconjugates?, Current Protein & Peptide Science 2003; 4 (1) . https://dx.doi.org/10.2174/1389203033380304
DOI https://dx.doi.org/10.2174/1389203033380304 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Update on Antifolate Drugs Targets
Current Drug Targets Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and In Vitro Anticancer Activity of Novel 2-((3-thioureido)carbonyl) phenyl Acetate Derivatives
Letters in Drug Design & Discovery Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings
Current Drug Discovery Technologies Editorial [Hot Topic: New Perspectives in the Treatment of Hematological Malignancies (Guest Editor: Masahiro Kizaki)]
Current Pharmaceutical Biotechnology New Experimental and Computational Tools for Drug Discovery. Part – XII
Current Topics in Medicinal Chemistry Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Cutting Edge: Chemoprevention of Colorectal Neoplasia in Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery